Structure Net Debt vs Deferred Long Term Liab Analysis
| GPCR Stock | 35.88 0.19 0.53% |
Structure Therapeutics financial indicator trend analysis is much more than just breaking down Structure Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Structure Therapeutics is a good investment. Please check the relationship between Structure Therapeutics Net Debt and its Deferred Long Term Liab accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Structure Therapeutics American. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Net Debt vs Deferred Long Term Liab
Net Debt vs Deferred Long Term Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Structure Therapeutics Net Debt account and Deferred Long Term Liab. At this time, the significance of the direction appears to have pay attention.
The correlation between Structure Therapeutics' Net Debt and Deferred Long Term Liab is -1.0. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Deferred Long Term Liab in the same time period over historical financial statements of Structure Therapeutics American, assuming nothing else is changed. The correlation between historical values of Structure Therapeutics' Net Debt and Deferred Long Term Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Structure Therapeutics American are associated (or correlated) with its Deferred Long Term Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Deferred Long Term Liab has no effect on the direction of Net Debt i.e., Structure Therapeutics' Net Debt and Deferred Long Term Liab go up and down completely randomly.
Correlation Coefficient | -1.0 |
| Relationship Direction | Negative |
| Relationship Strength | Strong |
Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Deferred Long Term Liab
Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.Most indicators from Structure Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Structure Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Structure Therapeutics American. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. At this time, Structure Therapeutics' Tax Provision is relatively stable compared to the past year. As of 05/17/2024, Selling General Administrative is likely to grow to about 34.3 M, while Enterprise Value Multiple is likely to drop (14.17).
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 122.2K | 1.5M | 13.4M | 14.1M | Depreciation And Amortization | 72.0 | 277K | 949.2K | 996.6K |
Structure Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Structure Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Structure Therapeutics American. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Structure Therapeutics information on this page should be used as a complementary analysis to other Structure Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Structure Stock analysis
When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Structure Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Structure Therapeutics. If investors know Structure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Structure Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.43) | Return On Assets (0.22) | Return On Equity (0.33) |
The market value of Structure Therapeutics is measured differently than its book value, which is the value of Structure that is recorded on the company's balance sheet. Investors also form their own opinion of Structure Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Structure Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Structure Therapeutics' market value can be influenced by many factors that don't directly affect Structure Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Structure Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Structure Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Structure Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.